Mylan PE Ratio 2006-2018 | MYL

Current and historical price to earnings ratio for Mylan (MYL) from 2006 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. The current PE ratio for Mylan as of August 17, 2018 is 8.37.
Mylan Annual PE Ratio
Mylan Quarterly PE Ratio
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $19.669B $11.908B
Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $63.001B 10.81
Teva Pharmaceutical Industries (TEVA) Israel $24.629B 6.88
Bausch Health Cos (BHC) Canada $7.633B 5.70
Dr Reddy's Laboratories (RDY) India $5.610B 25.06
Mallinckrodt Public (MNK) United Kingdom $2.887B 4.91
Akorn (AKRX) United States $2.382B 0.00
Supernus Pharmaceuticals (SUPN) United States $2.339B 25.03
Assembly Biosciences (ASMB) United States $0.930B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.824B 118.80
CymaBay Therapeutics (CBAY) United States $0.723B 0.00
Voyager Therapeutics (VYGR) United States $0.626B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.610B 0.00
Homology Medicines (FIXX) United States $0.607B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.589B 0.00
Corium (CORI) United States $0.324B 0.00
Teligent (TLGT) United States $0.228B 0.00
Sol-Gel Technologies (SLGL) Israel $0.119B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.111B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.071B 0.00
Aevi Genomic Medicine (GNMX) United States $0.069B 0.00
Versartis (VSAR) United States $0.065B 0.00
Evoke Pharma (EVOK) United States $0.041B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.020B 0.00
Acasti Pharma (ACST) Canada $0.017B 0.00
Agile Therapeutics (AGRX) United States $0.009B 0.00